White House Advisor Philipson Brings Industry-Aligned Views On Drug Value
Tomas Philipson, a University of Chicago professor and consultant to the pharmaceutical industry, is named to the White House Council of Economic Advisors.
You may also be interested in...
The US president made what seemed to be a retaliatory statement about high drug prices after Merck CEO Ken Frazier resigned from his jobs council.
The disconnect between what Donald Trump says about drug pricing in unscripted settings and what the Administration says in more formal, policy-articulating contexts is very stark. For biopharma companies, the 'official' statements are reassuring – but it would be dangerous to discount Trump’s populist instincts altogether.
Former senior advisor to President Trump warns that failure to reform drug pricing practices has seriously handicapped prospects for reimbursing cell and gene therapy under existing US payer programs.